EUVIMEDEUVIMED entdecken
Open Access

Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling

Yi-Fan Cong iD, Fu-Wang Liu, Li Xu, Shuang-Shuang Song, Xu-Ri Shen, Dong Liu, Xue-Qin Hou, Han-Ting Zhang

International Journal of Neuropsychopharmacology · 25.09.2023 · 26 (9) · 585-598

DOI: 10.1093/ijnp/pyad042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 25.07.2023. Verfasst von Yi-Fan Cong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Alzheimer Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Program of Brain Science and Brain-Like Intelligence Technology of the China Ministry of Science and Technology, Academic Promotion Program of Shandong First Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer disease (AD) and depression often cooccur, and inhibition of phosphodiesterase-4 (PDE4) has been shown to ameliorate neurodegenerative illness. Therefore, we explored whether PDE4 inhibitor rolipram might also improve the symptoms of comorbid AD and depression.

Methods

APP/PS1/tau mice (10 months old) were treated with or without daily i.p. injections of rolipram for 10 days. The animal groups were compared in behavioral tests related to learning, memory, anxiety, and depression. Neurochemical measures were conducted to explore the underlying mechanism of rolipram.

Results

Rolipram attenuated cognitive decline as well as anxiety- and depression-like behaviors. These benefits were attributed at least partly to the downregulation of amyloid-β, Amyloid precursor protein (APP), and Presenilin 1 (PS1); lower tau phosphorylation; greater neuronal survival; and normalized glial cell function following rolipram treatment. In addition, rolipram upregulated B-cell lymphoma-2 (Bcl-2) and downregulated Bcl-2-associated X protein (Bax) to reduce apoptosis; it also downregulated interleukin-1β, interleukin-6, and tumor necrosis factor-α to restrain neuroinflammation. Furthermore, rolipram increased cAMP, PKA, 26S proteasome, EPAC2, and phosphorylation of ERK1/2 while decreasing EPAC1.

Conclusions

Rolipram may mitigate cognitive deficits and depression-like behavior by reducing amyloid-β pathology, tau phosphorylation, neuroinflammation, and apoptosis. These effects may be mediated by stimulating cAMP/PKA/26S and cAMP/exchange protein directly activated by cAMP (EPAC)/ERK signaling pathways. This study suggests that PDE4 inhibitor rolipram can be an effective target for treatment of comorbid AD and depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsAlzheimer DiseaseMiceAnimalsAmyloid beta-Protein PrecursorRolipramMice, TransgenicNeuroinflammatory DiseasesPresenilin-1DepressionAmyloid beta-PeptidesMemory DisordersApoptosisDisease Models, Animal

Stichwörter der Autor:innen

3×Tg-AD miceAlzheimer diseasedepressionphosphodiesterase-4rolipram

Substanzen

Amyloid beta-Protein PrecursorRolipramPhosphodiesterase 4 InhibitorsPresenilin-1Amyloid beta-Peptides

Autor:innen und Institutionen

  • Institute of Pharmacology, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China.
  • Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, P.R. China.

ORCID-Profile: Yi-Fan Cong

Förderung

  • National Natural Science Foundation of China
  • Key Program of Brain Science and Brain-Like Intelligence Technology of the China Ministry of Science and Technology
  • Academic Promotion Program of Shandong First Medical University
  • Key Project by Qingdao Bureau of Sciences and Technology
  • Guilin Medical University

Zitieren

APA

Cong, Y. F., Liu, F. W., Xu, L., Song, S. S., Shen, X. R., Liu, D., Hou, X. Q., & Zhang, H. T. (2023). Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling. International Journal of Neuropsychopharmacology, 26(9), 585-598. https://doi.org/10.1093/ijnp/pyad042

Vancouver

Cong YF, Liu FW, Xu L, Song SS, Shen XR, Liu D, et al. Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling. International Journal of Neuropsychopharmacology. 2023;26(9):585-598. doi:10.1093/ijnp/pyad042

BibTeX
@article{Cong2023,
  author = {Cong, Yi-Fan and Liu, Fu-Wang and Xu, Li and Song, Shuang-Shuang and Shen, Xu-Ri and Liu, Dong and Hou, Xue-Qin and Zhang, Han-Ting},
  title = {Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2023},
  volume = {26},
  number = {9},
  pages = {585--598},
  doi = {10.1093/ijnp/pyad042}
}
Kostenlos starten →